Delisting risk
MIRA · NASDAQ · Drug Manufacturers - General

MIRA Pharmaceuticals (MIRA)

Develops oral small-molecule candidates for pain, obesity, and addiction-related disorders.

$0.8600
Pre-market−0.01 (−0.58%)
At close$0.8650(+0.58%)

Something off on this page? Send us feedback.

Next report
Dec 2, 2026
estimated · in 90 days
EPS estimate
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Dec '26
Reported−$0.15−$0.11−$0.09−$1.18−$0.15−$0.03−$0.03Pending
Estimate−$0.29−$0.15−$0.11−$1.18−$0.04
Surprise+48.3%+26.7%+18.2%0.0%−275.0%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Dec '26
Reported$11.2MPending
Estimate
Surprise

History

DateEstimateReportedSurprise
Dec 2026
Aug 2026−$0.03
May 2026−$0.03
Mar 2026−$0.04−$0.15−275.0%
Nov 2025−$1.18−$1.180.0%

The latest year is open to everyone — the 15 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Apr 2024
Nov 2023
Sep 2023
Mar 2023
Dec 2022
Sep 2022
Jun 2022
Mar 2022
Mar 2021
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Dec 2, 2026
Aug 12, 2026−$0.03−5.0%
May 14, 2026−$0.03−1.2%
Mar 31, 2026−$0.04−$0.15−275.0%−0.9%
Nov 13, 2025−$1.18−$1.180.0%+3.0%

The latest year is open to everyone — the 15 quarters behind it read with an account.

Sign in
Aug 14, 2025
May 14, 2025
Mar 28, 2025
Nov 12, 2024
Aug 13, 2024
May 13, 2024
Apr 1, 2024
Nov 13, 2023
Sep 15, 2023
Mar 31, 2023
Dec 31, 2022
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Mar 31, 2021